Tesla is valued like a platform, not just for its enormously successful covet vaccine, but for what comes next. Maderna is the opposite. It looks reasonable now because they're generating enormous sales sprum from their cove vakin tu go a few years later. Because it's going to be quite some time before the rest of its pipe line arrive.
Dr. Ian Lustbader, Clinical Professor of Medicine at NYU Langone, discusses the FDA approval of a third Covid vaccine shot for people with weak immune systems. Bloomberg Businessweek Editor Joel Weber and Bloomberg News U.S. Health Care Reporter Cynthia Koons discuss Cynthia's Businessweek Magazine story Don’t Lose Sight of Fact That Covid Vaccines Are Working. Bloomberg Opinion Healthcare Columnist Max Nisen discusses the "Tesla-fication"of Moderna. And we Drive to the Close with Rebecca Corbin, CEO of Corbin Advisors.
Host: Carol Massar. Producer: Paul Brennan.
See omnystudio.com/listener for privacy information.